-
Nvidia (NVDA) is projected to reach sales of $56.8 billion next week, as reported by Citi. Ahead of the earnings announcement, several firms are raising their price targets.
-
Guggenheim upgraded Sunrun (RUN) to a buy, suggesting it’s a prime acquisition target with a price target of $27, based on potential returns expected by 2026.
-
Eli Lilly (LLY) has made a deal to lower the prices for GLP-1 treatments under Medicare and Medicaid to $245 a month starting in mid-2026.
-
While some investors find wealth, others face challenges due to differing strategies for building it. It’s important to recognize these differences.
The market seems to be gaining momentum. There’s a bit of relief with news suggesting that the government shutdown might soon wrap up. Recently, Democrats and some Republicans voted 60-40 to move forward, and now we just have to wait for the final vote in the House of Commons.
In the meantime, analysts have some interesting insights to share.
NVIDIA (NASDAQ: NVDA): Ahead of Nvidia’s impending earnings report, Citi analysts reaffirmed their buy recommendation, setting a price target between $210 and $220. Nvidia is anticipating sales of $56.8 billion, which beats the $54.6 billion most analysts had expected.
Bank of America has also maintained a buy stance on Nvidia, highlighting the company’s strong positioning in both healthcare and AI. They remarked, “Nvidia is leading in accelerated computing and is actively partnering to expand its influence in high-performance medical applications,” as quoted by CNBC.
Moreover, UBS analysts project that Nvidia will generate fourth-quarter revenue between $63 billion and $64 billion. Their current investment stance is “buy,” with a target price set at $235.
Sunrun (NASDAQ: RUN): Guggenheim has upgraded RUN to a buy, describing the current price as attractive. The analysts see a price target of $27 based on positive outlook for returns by 2026.
Earlier this month, Jefferies raised their rating on RUN to “buy” with a price target of $21, up from $11, anticipating strong cash creation soon. BMO has also upped its target on RUN from $10 to $19, citing that they expect significant cash generation next year, potentially allowing for stock buybacks or dividends.
Eli Lilly (NYSE: LLY): Leerink analysts just elevated LLY to an outperform rating. They point out that by January 2027, there should be significant adoption of obesity treatments, owing to expanded Medicare and Medicaid access.
